AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...

Find insight on AstraZeneca, Fresenius, ConvaTec, and more in the latest Market Talks covering the Health Care sector.

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...